Report cover image

Global Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Feb 07, 2025
Length 194 Pages
SKU # APRC20120819

Description

Summary

According to APO Research, The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
Novartis
SIEMENS
Bayer
Dongcheng
Eli Lilly
China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology
Cardiology
Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Radiopharmaceuticals in Nuclear Medicine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceuticals in Nuclear Medicine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Radiopharmaceuticals in Nuclear Medicine Market by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.3 Radiopharmaceuticals in Nuclear Medicine Market by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Global Market Growth Prospects
3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue Estimates and Forecasts (2020-2031)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2020-2025)
3.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2026-2031)
3.2.4 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2020-2031)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts 2020-2031
3.4 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
3.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2025)
3.4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2026-2031)
3.4.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2020-2025)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2020-2025)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Manufacturers (2020-2025)
4.4 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application
4.7 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
4.8.2 2024 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3
5 Radiopharmaceuticals in Nuclear Medicine Market by Type
5.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2020-2031)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031) & (K Units)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2020-2031)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type
6 Radiopharmaceuticals in Nuclear Medicine Market by Application
6.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
6.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2020-2031)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031) & (K Units)
6.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2020-2031)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application
7 Company Profiles
7.1 Aurobindo Pharma
7.1.1 Aurobindo Pharma Comapny Information
7.1.2 Aurobindo Pharma Business Overview
7.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.1.5 Aurobindo Pharma Recent Developments
7.2 Bracco Imaging
7.2.1 Bracco Imaging Comapny Information
7.2.2 Bracco Imaging Business Overview
7.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.2.5 Bracco Imaging Recent Developments
7.3 Cardinal Health
7.3.1 Cardinal Health Comapny Information
7.3.2 Cardinal Health Business Overview
7.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.3.5 Cardinal Health Recent Developments
7.4 Curium Pharma
7.4.1 Curium Pharma Comapny Information
7.4.2 Curium Pharma Business Overview
7.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.4.5 Curium Pharma Recent Developments
7.5 GE Healthcare
7.5.1 GE Healthcare Comapny Information
7.5.2 GE Healthcare Business Overview
7.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.5.5 GE Healthcare Recent Developments
7.6 Jubilant Pharma
7.6.1 Jubilant Pharma Comapny Information
7.6.2 Jubilant Pharma Business Overview
7.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.6.5 Jubilant Pharma Recent Developments
7.7 Lantheus
7.7.1 Lantheus Comapny Information
7.7.2 Lantheus Business Overview
7.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.7.5 Lantheus Recent Developments
7.8 Mundipharma
7.8.1 Mundipharma Comapny Information
7.8.2 Mundipharma Business Overview
7.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.8.5 Mundipharma Recent Developments
7.9 Novartis
7.9.1 Novartis Comapny Information
7.9.2 Novartis Business Overview
7.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.9.5 Novartis Recent Developments
7.10 SIEMENS
7.10.1 SIEMENS Comapny Information
7.10.2 SIEMENS Business Overview
7.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.10.5 SIEMENS Recent Developments
7.11 Bayer
7.11.1 Bayer Comapny Information
7.11.2 Bayer Business Overview
7.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.11.5 Bayer Recent Developments
7.12 Dongcheng
7.12.1 Dongcheng Comapny Information
7.12.2 Dongcheng Business Overview
7.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.12.5 Dongcheng Recent Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Comapny Information
7.13.2 Eli Lilly Business Overview
7.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.13.5 Eli Lilly Recent Developments
7.14 China Isotope & Radiation
7.14.1 China Isotope & Radiation Comapny Information
7.14.2 China Isotope & Radiation Business Overview
7.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
7.14.5 China Isotope & Radiation Recent Developments
8 North America
8.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Type
8.1.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
8.1.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
8.1.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
8.2 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Application
8.2.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
8.2.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
8.2.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
8.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
8.3.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Type
9.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
9.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
9.1.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
9.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Application
9.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
9.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
9.2.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
9.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country
9.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Radiopharmaceuticals in Nuclear Medicine Market Size by Type
10.1.1 China Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
10.1.2 China Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
10.1.3 China Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
10.2 China Radiopharmaceuticals in Nuclear Medicine Market Size by Application
10.2.1 China Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
10.2.2 China Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
10.2.3 China Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Type
11.1.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
11.1.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
11.1.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
11.2 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Application
11.2.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
11.2.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
11.2.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
11.3 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Country
11.3.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Type
12.1.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
12.1.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
12.1.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
12.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Application
12.2.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
12.2.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
12.2.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
12.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Country
12.3.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
13.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
13.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
13.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.